Breaking the relapse barrier: innovative approaches to improve CAR T-cell efficacy by targeting leukemic stem cells (LSCs) and measurable residual disease (MRD) in acute myeloid leukemia.
This review critically reviews the molecular signatures and protective mechanisms of relapse-initiating cells and introduces innovative CAR T cell engineering strategies that are aimed at disrupting the bone marrow niche, eliminating malignant stemness, overcoming exhaustion of engineered T cells and redefining the the...